CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
08 Oct 2020
08 Oct 2020
Historique:
pubmed:
15
10
2020
medline:
15
10
2020
entrez:
14
10
2020
Statut:
epublish
Résumé
Characterization of the T cell response in individuals who recover from SARS-CoV-2 infection is critical to understanding its contribution to protective immunity. A multiplexed peptide-MHC tetramer approach was used to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition in a cross-sectional sample of 30 COVID-19 convalescent individuals. T cells were evaluated using a 28-marker phenotypic panel, and findings were modelled against time from diagnosis, humoral and inflammatory responses. 132 distinct SARS-CoV-2-specific CD8+ T cell epitope responses across six different HLAs were detected, corresponding to 52 unique reactivities. T cell responses were directed against several structural and non-structural virus proteins. Modelling demonstrated a coordinated and dynamic immune response characterized by a decrease in inflammation, increase in neutralizing antibody titer, and differentiation of a specific CD8+ T cell response. Overall, T cells exhibited distinct differentiation into stem-cell and transitional memory states, subsets, which may be key to developing durable protection.
Identifiants
pubmed: 33052343
doi: 10.1101/2020.10.08.330688
pmc: PMC7553170
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL151826
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120938
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128779
Pays : United States
Déclaration de conflit d'intérêts
Competing interests: H.K., H.S., F.K., D.C., B.A., A.N., E.W.N., and M.F. are shareholders and/or employees of ImmunoScape Pte Ltd. A.N. is a Board Director of ImmunoScape Pte Ltd.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
PLoS Pathog. 2013;9(6):e1003422
pubmed: 23818845
J Immunother Cancer. 2019 Sep 12;7(1):249
pubmed: 31511069
Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Nat Biotechnol. 2013 Jul;31(7):623-9
pubmed: 23748502
J Exp Med. 1999 Sep 6;190(5):705-15
pubmed: 10477554
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
Sci Immunol. 2017 Jun 2;2(12):
pubmed: 28783656
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Nat Commun. 2018 Jul 26;9(1):3000
pubmed: 30050138
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Commun. 2020 Feb 10;11(1):821
pubmed: 32041953
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330